ProKidney (NASDAQ:PROK) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

ProKidney (NASDAQ:PROK) announced its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Zacks reports. The firm had revenue of $0.08 million during the quarter.

ProKidney Trading Up 5.7 %

Shares of NASDAQ:PROK opened at $1.04 on Tuesday. ProKidney has a 12-month low of $0.94 and a 12-month high of $4.44. The stock’s 50-day moving average price is $1.48 and its two-hundred day moving average price is $1.77. The firm has a market cap of $303.33 million, a price-to-earnings ratio of -1.89 and a beta of 1.38.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.